查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827440

肝癌藥物市場按治療類型、癌症類型、給藥途徑、藥物類別、最終用戶和分銷管道分類－2025-2032 年全球預測

Liver Cancer Drugs Market by Therapy Type, Cancer Type, Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝癌治療市場規模將成長至 29.0638 億美元，複合年成長率為 14.44%。

主要市場統計數據
基準年2024年 9.876億美元
預計2025年 1,127,840,000美元
預測年份：2032年 2,906,380,000美元
複合年成長率（%） 14.44%

免疫腫瘤學整合、精準醫療和複雜的遞送挑戰推動肝癌治療模式的不斷發展

肝癌治療正處於曲折點，其特徵是科學進步日新月異、臨床模式不斷轉變以及商業性動態不斷演變。近年來，免疫腫瘤學方法與成熟的標靶治療和細胞毒性方案的穩步整合，催生了結合全身和局部干預的多學科治療途徑。因此，臨床醫生、付款方和製造商正在重新評估治療流程，以最佳化治療效果，同時克服藥物可近性障礙和複雜的報銷環境。

從傳統的單藥治療模式轉向組合方案的轉變，為臨床開發、監管核准和市場部署帶來了新的機遇，也帶來了新的複雜性。透過分子分析進行患者分層，以及真實世界證據日益成長的重要性，正在重塑臨床試驗設計和核准後證據的生成。因此，策略性相關人員必須在創新與實際考量（例如供應鏈彈性、定價策略和相關人員教育）之間取得平衡，以確保治療進展能夠轉化為患者的福祉。

最終，現代醫療格局需要一個獎勵觀點，將不斷發展的科學、多方相關人員以及不同環境下醫療服務的現實納入考量。本引言為深入探討顛覆性變革、政策影響、細分市場細微差別、地理差異、競爭模式以及本執行摘要摘要之後的行動建議奠定了基礎。

免疫腫瘤學的突破、精準診斷和新型給藥模式如何重新定義肝癌的治療和護理

由於免疫療法、標靶小分子藥物和聯合治療的突破，肝癌治療格局正在發生重大轉變。查核點抑制劑和抗血管新生藥物的組合改變了一線治療途徑，而針對特定分子異常的標靶抑制劑則為此前服務不足的亞群拓展了治療選擇。同時，診斷準確性的提高（包括更廣泛的分子譜分析）使患者能夠更精確地匹配治療方法，從而加速了個人化治療方案的進程。

由於部分聯合治療已被證明在生存和耐受性方面均具有臨床益處，支付方和醫療機構系統正在重新調整治療路徑，以納入這些創新。這種調整正在推動腫瘤中心、診斷實驗室和專科藥房之間建立新的合作，以提供一體化治療。此外，口服標靶治療和皮下注射劑型的興起正在改變給藥模式，並促成門診和居家護理模式，從而減輕住院負擔，並提高患者便利性。

同時，監管框架也在不斷發展，以適應適應性試驗設計和加速核准途徑，鼓勵申辦方追求新的終點和替代指標。因此，治療軌跡不僅由科學進步決定，還受到醫療保健服務、監管互動和商業性執行的系統性轉變的影響，這些轉變共同重新定義了肝臟惡性腫瘤的最佳治療方案。

評估2025年關稅變化如何增加供應鏈脆弱性、影響定價結構並加速本地生產策略

2025年關稅的實施和貿易政策的變化凸顯了全球醫藥供應鏈和採購慣例中現有的脆弱性，對肝癌治療生態系統產生了累積影響。活性藥物原料藥、輔料和成品的進口關稅提高，增加了製造商和經銷商的到岸成本，促使他們重新評估籌資策略，並可能調整其商業定價模式。因此，醫療保健提供者和付款人可能面臨影響處方決策和患者可及性計劃的定價壓力。

此外，關稅可能會加速製造業在地化進程，增強區域供應彈性，鼓勵對地理分散的生產能力和策略性儲備進行投資。雖然回流和近岸外包可以緩解未來的中斷風險​​，但也會帶來短期資本支出，以及與建立合規製造地相關的監管複雜性。因此，無論是市場參與企業或現有企業，在規劃製造地時都必須權衡成本、敏捷性和合規性之間的優點和缺點。

此外，貿易政策波動可能會影響臨床試驗的供應計劃以及患者篩選所需的專用檢測試劑的可用性，從而可能影響下游的入組和試驗時間表。對於跨多個司法管轄區營運的相關人員而言，關稅增加了一層戰略不確定性，凸顯了靈活的合約、嚴格的供應商資格以及與付款方積極溝通的重要性，以便在成本結構不斷變化的情況下維持患者的可及性。

全面的細分洞察揭示了治療方式、癌症亞型、給藥途徑和通路如何影響治療的採用

市場區隔分析透過從治療類型、癌症亞型、給藥途徑、藥物類別、最終用戶和通路方面構建市場框架，為理解肝癌的治療需求和治療方案的實施提供了細緻入微的視角。按治療類型（例如化療、免疫療法、放射線治療和標靶治療）對治療進行分類，使我們能夠觀察到不同治療方案的臨床發展軌跡和資源影響。同樣，按癌症類型（例如膽管癌、肝母細胞瘤和肝細胞癌）進行細分，可以揭示未滿足需求的差異、受年齡和生物學影響的治療選擇以及利基創新機會。

按給藥途徑（包括靜脈注射、口服和皮下注射）進行細分，揭示了給藥方式如何影響患者依從性、門診病人利用率和治療經濟性。依藥物類別，我們區分了細胞毒性藥物、單株抗體和蛋白酪氨酸激酶抑制劑，每種藥物都有其獨特的安全性、監測和開發特性，決定了其臨床應用。將最終用戶細分為居家醫療、醫院和專科診所，揭示了治療的運作途徑以及相應的患者教育和監測要求。

最後，一項涵蓋醫院、線上和零售藥局的分銷管道分析，揭示了獲取途徑、履約的複雜性以及數位化和專業配藥模式的演變。這些細分觀點可以幫助相關人員確定有針對性的商業化策略，優先考慮亞群體的證據生成，並設計符合臨床實踐和患者偏好的交付模式。

影響美洲、歐洲、中東和非洲以及亞太地區治療採用和交付的差異化因素和可近性推動因素

區域動態對治療方法的可近性、監管途徑和商業策略有重大影響，美洲、歐洲、中東和非洲以及亞太地區之間存在明顯差異。在美洲，先進的腫瘤學基礎設施、廣泛的臨床試驗網路以及先進的報銷框架使得新型系統性治療方案能夠相對快速地被採用。專科醫療中心的地理集中也有利於對複雜病例進行加護治療，但在貧困地區，治療可近性仍有差異。

歐洲、中東和非洲地區管理體制和醫療資金籌措模式的差異，導致醫療服務的可近性和採用率參差不齊。高所得的歐洲市場通常能夠更快地採納指南建議和更廣泛的報銷途徑，而資源受限的地區則必須在高成本創新與相互競爭的醫療保健優先事項之間取得平衡，這導致人們對分級定價和可及性計劃的興趣日益濃厚。中東和非洲部分地區在基礎設施和診斷能力方面面臨獨特的挑戰，因此需要採取獨特的採用方法。

亞太地區呈現出多元化的頻譜，既有由大型公共衛生系統和積極的國內製造業推動的先進市場，也有診斷能力和分銷物流仍在不斷擴展的新興市場。監管現代化努力和本地臨床開發夥伴關係是該地區的突出趨勢，既支持全球臨床項目，也支持地方治療創新。在整個地區，跨境合作、技術支援的醫療模式和自適應報銷機制正在成為擴大病患可近性的重要槓桿。

策略企業模式展示了研發聯盟、投資組合多樣化和現實世界證據策略如何塑造競爭定位

肝癌治療領域的關鍵企業行動體現了一系列策略性研發投資、合作活動和生命週期管理，旨在實現長期成長並維持臨床相關性。製藥和生技公司越來越重視利用互補作用機制的組合方案，同時也投資伴隨診斷，以改善患者選擇並向付款人展示價值。大型跨國公司與專業生技公司之間的策略聯盟十分常見，有助於加快新藥上市速度並共用開發風險。

藥物研發管線多元化是核心主題，各公司在小分子激酶抑制劑和細胞毒性藥物計畫與生物製藥、抗體藥物複合體和免疫調節平台之間尋求平衡。各公司也專注於開發支持門診治療的劑型和給藥途徑，例如口服和皮下給藥，以應對不斷變化的醫療服務提供者的偏好。從商業性角度來看，各公司正在擴展患者支援服務和基於價值的安排，以減少藥物取得障礙並加強與付款人的關係。

併購和選擇性授權交易仍然是加速獲取有前景的資產和增強治療組合的重要槓桿。同時，企業越來越注重真實世界證據的生成和上市後監測，以最佳化定位、管理安全性並為迭代核准提交提供資訊。總而言之，這些企業策略體現了科學抱負與商業性紀律的務實融合。

為產業領導者提供切實可行的策略指令，以增強供應彈性、精準診斷和以價值為中心的商業化方法

行業領導者必須採取一系列切實可行的措施，以應對快速發展的肝癌治療格局，並確保患者永續獲得藥物並實現商業性可行性。首先，他們應優先考慮供應鏈多元化和策略供應商資格認證，以減少對單一供應商的依賴，並最大限度地降低貿易政策波動和原料限制造成的中斷風險​​。投資區域製造能力和靈活的生產平台可以提高韌性，並加快關鍵治療方法的上市時間。

其次，相關人員應投資強大的分子診斷能力和伴隨診斷夥伴關係，以實現精準的病患選擇、改善臨床結果並加強報銷案例。第三，付款方和提供者應合作推行基於價值的合約和基於結果的定價模式，使付款與實際績效保持一致，從而減輕定價壓力並促進醫療可及性。第四，整合數位醫療工具、遠端醫療和遠端監控的跨部門合作可以擴大服務涵蓋範圍，涵蓋服務不足的人群，並支持患者堅持口服或皮下注射治療方案。

最後，公司應從開發早期階段就優先考慮與監管機構和付款方進行透明的溝通，以協調證據要求，並切實設計核准後的證據生成計劃。透過將以臨床為中心的商業化策略與營運韌性相結合，產業領導者可以加速創新治療方法的採用，同時確保長期永續性。

我們的方法框架將專家的初步研究與嚴格的二次研究相結合，以檢驗臨床、監管和商業見解

這項綜合性研究採用混合方法，將專家的主要意見與全面的二次分析相結合，旨在為肝癌藥物提供穩健且站得住腳的觀點。主要研究包括與臨床意見領袖、腫瘤藥劑師、付款人代表和高級商業高管進行結構化訪談和諮詢，以了解現實世界的實踐模式、報銷動態和戰略重點。這些專家見解被用於整理趨勢並檢驗從文獻分析中得出的主題。

二次研究包括系統性地查閱同行評審文獻、監管指南文件、臨床試驗註冊中心和公司資訊披露，以繪製治療方法進展、試驗結果和證據軌跡。整合來自公共衛生組織和專業協會指南的訊息，以了解護理標準和診斷採用模式的變化。透過交叉引用多個獨立資訊來源和反覆專家檢驗，確保數據品質。

本調查方法的局限性包括臨床證據和政策環境的演變，這些因素在研究期結束後可能會發生變化。為了緩解這一局限性，該方法強調數據來源的透明記錄，並鼓勵持續監測監管決策和關鍵臨床結果。該調查方法兼顧深度和廣度，以支持戰略決策，同時也認知到隨著領域發展需要定期更新。

最終的綜合報告強調，需要協調科學創新、營運彈性和以付款人為中心的證據，以將治療方法進展轉化為患者利益

總而言之，肝癌治療領域正在再形成：免疫腫瘤學和標靶藥物的科學創新、不斷發展的醫療服務提供和管理方法，以及貿易政策和區域可及性差異等外部壓力。這些力量正在創造改善患者預後的新機遇，同時也帶來了營運和報銷方面的複雜性，產業、醫療服務提供者和付款人必須共同應對。最終的結果是，一個更具活力、以病人為中心的環境將更有利於精準、靈活和實證的商業化。

展望未來，重視診斷整合、供應鏈韌性和以支付者為導向的價值展示的相關人員將更有能力將創新轉化為持續的臨床和商業性成功。此外，適應性監管參與和策略夥伴關係（包括臨床和商業）仍將是加速患者可及性的關鍵槓桿。最終，能否將科學前景與實際應用結合，將決定治療方法為肝癌患者族群帶來持續的益處。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 免疫查核點抑制劑聯合治療在晚期肝細胞癌治療的應用日益增多
  • 基於基因分析的生物標記主導的精準醫療在肝癌治療中的整合
  • 擴大肝動脈栓塞合併全身性治療治療中期肝細胞癌
  • 針對肝癌抗原的下一代 CAR-T 和 T 細胞受體療法的開發
  • 真實世界證據和數位健康監測在肝細胞癌治療中的重要性日益增加
  • 肝癌治療中新型多激酶抑制劑的市場進入挑戰與定價策略

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章肝癌藥物市場（依治療類型）

  • 化療
  • 免疫療法
  • 放射治療
  • 標靶治療

第9章肝癌治療藥物市場（按癌症類型）

  • 膽管癌
  • 肝母細胞瘤
  • 肝細胞癌（HCC）

第10章肝癌治療藥物市場依給藥途徑

  • 靜脈
  • 口服
  • 皮下

第11章肝癌藥物市場（依藥物類別）

  • 細胞毒性藥物
  • 單株抗體
  • 蛋白酪氨酸激酶抑制劑（TKI）

第12章肝癌藥物市場（依最終用戶）

  • 居家護理
  • 醫院
  • 專科診所

第13章肝癌藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第14章肝癌藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章肝癌藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章肝癌藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Bayer AG
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Ipsen SA
    • AstraZeneca plc
    • Exelixis, Inc.
Product Code: MRR-434CCDA05287

The Liver Cancer Drugs Market is projected to grow by USD 2,906.38 million at a CAGR of 14.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 987.60 million
Estimated Year [2025] USD 1,127.84 million
Forecast Year [2032] USD 2,906.38 million
CAGR (%) 14.44%

An evolving therapeutic paradigm in liver oncology driven by immuno-oncology integration, precision medicine, and complex delivery challenges

Liver cancer therapeutics are at an inflection point, characterized by rapid scientific advances, shifting clinical paradigms, and evolving commercial dynamics. Recent years have seen the steady integration of immuno-oncology approaches alongside established targeted therapies and cytotoxic regimens, prompting multidisciplinary care pathways that blend systemic treatments with locoregional interventions. As a result, clinicians, payers, and manufacturers are re-evaluating treatment algorithms to optimize outcomes while navigating access barriers and complex reimbursement environments.

Transitioning from historical monotherapy models to combination regimens has created new opportunities and new complexities for clinical development, regulatory approval, and market deployment. Patient stratification through molecular profiling and the growing importance of real-world evidence are reshaping trial design and post-approval evidence generation. Consequently, strategic stakeholders must balance innovation with pragmatic considerations such as supply chain resilience, pricing strategies, and stakeholder education to ensure that therapeutic advances translate into measurable patient benefit.

Ultimately, the modern landscape demands an integrated perspective that accounts for evolving science, multi-stakeholder incentives, and the operational realities of delivering care across diverse settings. This introduction sets the stage for a deeper exploration of the disruptive shifts, policy influences, segmentation nuances, geographic differentials, competitive maneuvers, and recommended actions that follow in this executive summary.

How immuno-oncology breakthroughs, precision diagnostics, and novel administration models are collectively redefining liver cancer treatment and care delivery

The liver cancer treatment landscape has undergone transformative shifts driven by breakthroughs in immunotherapy, targeted small molecules, and combination strategies. Checkpoint inhibition paired with antiangiogenic agents has altered frontline care pathways, while targeted inhibitors for specific molecular aberrations have expanded options for previously underserved subpopulations. Concurrently, improvements in diagnostic precision, including more widespread molecular profiling, have made it possible to match patients to therapies with greater accuracy, accelerating the move toward personalized regimens.

As clinical benefits have been demonstrated in both survival and tolerability for select combinations, payer and provider systems are recalibrating care pathways to incorporate these innovations. This recalibration has prompted new collaborations between oncology centers, diagnostic laboratories, and specialty pharmacies to deliver integrated care. Moreover, the growth of oral targeted therapies and subcutaneous formulations is changing administration dynamics, enabling more outpatient and home-based care models that reduce hospital burden and improve patient convenience.

In parallel, regulatory frameworks are evolving to accommodate adaptive trial designs and accelerated approval pathways, which has encouraged sponsors to pursue novel endpoints and surrogate markers. As a result, the therapeutic trajectory is defined not only by scientific advances but by systemic shifts in care delivery, regulatory interaction, and commercial execution that together are redefining what constitutes best-in-class treatment for liver malignancies.

Assessment of how 2025 tariff shifts are compounding supply chain fragility, influencing pricing structures, and accelerating localized manufacturing strategies

The introduction of tariffs and trade policy shifts in 2025 has had a cumulative impact on the liver cancer therapeutic ecosystem by accentuating pre-existing vulnerabilities in global pharmaceutical supply chains and procurement practices. Increased import duties on active pharmaceutical ingredients, excipients, and finished formulations can raise landed costs for manufacturers and distributors, prompting reassessment of sourcing strategies and potential adjustments to commercial pricing models. In turn, healthcare providers and payers may face pricing pressures that influence formulary decisions and patient access programs.

Moreover, tariffs can accelerate efforts to regionalize manufacturing and strengthen local supply resilience, prompting investment in geographically diversified production capacity and strategic stockpiling. While reshoring and nearshoring efforts can mitigate future disruption risk, they also introduce short-term capital expenditures and regulatory complexities associated with establishing compliant manufacturing sites. Consequently, market entrants and incumbents must weigh the trade-offs between cost, agility, and compliance in planning their manufacturing footprints.

Furthermore, trade policy volatility may affect the cadence of clinical trial supplies and the availability of specialized assays required for patient selection, with potential downstream impacts on enrollment and study timelines. For stakeholders operating across multiple jurisdictions, tariffs add a layer of strategic uncertainty that underscores the importance of flexible contracting, robust supplier qualification, and proactive engagement with payers to preserve patient access amidst shifting cost structures.

Comprehensive segmentation insights revealing how therapy modalities, cancer subtypes, administration routes, and distribution pathways shape treatment adoption

Segmentation analyses provide a nuanced lens to understand therapeutic demand and delivery in liver cancer by framing the market across therapy type, cancer subtype, administration route, drug class, end user, and distribution channel. When treatments are categorized by therapy type such as chemotherapy, immunotherapy, radiation therapy, and targeted therapy, one can observe distinct clinical trajectories and resource implications across lines of care. Similarly, segmenting by cancer type-covering cholangiocarcinoma, hepatoblastoma, and hepatocellular carcinoma-illuminates differential unmet needs, age- and biology-driven treatment choices, and opportunities for niche innovation.

Administration route segmentation, which includes intravenous, oral, and subcutaneous options, reveals how delivery modality affects patient adherence, outpatient utilization, and the economics of care. Examination by drug class differentiates cytotoxic agents from monoclonal antibodies and tyrosine kinase inhibitors, each bringing a unique safety, monitoring, and development profile that shapes clinical adoption. End user segmentation across home care, hospitals, and specialty clinics highlights the operational pathways through which therapies are delivered and the corresponding requirements for patient education and monitoring.

Finally, distribution channel analysis, spanning hospital pharmacy, online pharmacy, and retail pharmacy, sheds light on access pathways, fulfillment complexity, and the evolving role of digital and specialty dispensing models. Taken together, these segmentation perspectives enable stakeholders to identify targeted commercialization strategies, prioritize evidence generation in subpopulations, and design delivery models that align with clinical practice and patient preferences.

Regional differentiators and access enablers across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence therapeutic adoption and delivery

Regional dynamics exert a strong influence on therapy availability, regulatory pathways, and commercial strategies, with clear distinctions across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced oncology infrastructures, broad clinical trial networks, and progressive reimbursement frameworks have enabled relatively rapid adoption of novel systemic regimens, while payer scrutiny and cost-effectiveness evaluations increasingly shape lifecycle management of therapies. Geographic concentration of specialty centers also facilitates centralized care for complex cases, but disparities in access persist in under-resourced areas.

Within Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare financing models produce a patchwork of access and uptake. High-income European markets often see quicker alignment with guideline recommendations and broader reimbursement pathways, whereas regions with constrained resources must balance high-cost innovations against competing health priorities, driving interest in tiered pricing and access programs. The Middle East and parts of Africa face distinct infrastructure and diagnostic capacity challenges that require tailored implementation approaches.

Asia-Pacific exhibits a spectrum from advanced market adoption, driven by large public health systems and active domestic manufacturing, to emerging markets where diagnostic capacity and distribution logistics are still expanding. Regulatory modernization efforts and local clinical development partnerships are notable trends in the region, supporting both global clinical programs and regionally specific therapeutic innovations. Across all regions, cross-border collaboration, technology-enabled care models, and adaptive reimbursement mechanisms are emerging as critical enablers of broader patient access.

Strategic corporate patterns showing how R&D alliances, portfolio diversification, and real-world evidence strategies are shaping competitive positioning

Key corporate behaviors in the liver cancer therapeutics arena reveal a mix of strategic R&D investment, partnering activity, and lifecycle management aimed at sustaining long-term growth and clinical relevance. Pharmaceutical and biotechnology companies are increasingly prioritizing combination regimens that leverage complementary mechanisms of action, while also investing in companion diagnostics to improve patient selection and demonstrate value to payers. Strategic alliances between large multinationals and specialist biotech firms are commonplace, enabling speed-to-market for novel agents and the sharing of development risk.

Pipeline diversification is a central theme, with firms balancing small-molecule kinase inhibitors and cytotoxic programs alongside biologics, antibody-drug conjugates, and immune-modulating platforms. Companies are also focused on developing formulations and administration routes that support outpatient care, including oral and subcutaneous options that align with shifting provider preferences. From a commercial perspective, leaders are expanding patient support services and value-based arrangements to mitigate access hurdles and strengthen payer relationships.

Mergers and acquisitions, as well as selective licensing deals, remain important tools for accelerating access to promising assets and augmenting therapeutic portfolios. In parallel, firms are placing greater emphasis on real-world evidence generation and post-marketing surveillance to refine positioning, manage safety considerations, and inform iterative regulatory submissions. Collectively, these corporate strategies underscore a pragmatic convergence of scientific ambition and commercial discipline.

Actionable strategic directives for industry leaders to strengthen supply resilience, precision diagnostics, and value-focused commercialization approaches

Industry leaders must adopt a set of pragmatic, actionable measures to navigate the rapidly evolving liver cancer therapeutics landscape and to ensure sustainable patient access and commercial viability. First, supply chain diversification and strategic supplier qualification should be prioritized to reduce dependency on single-source suppliers and to minimize the disruption risk posed by trade policy fluctuations or raw material constraints. Investments in regional manufacturing capacity and flexible production platforms can both improve resilience and shorten time-to-market for critical therapies.

Second, stakeholders should invest in robust molecular diagnostic capabilities and companion diagnostic partnerships to enable precise patient selection, which enhances clinical outcomes and strengthens reimbursement cases. Third, value-based contracting and outcomes-based pricing models should be pursued in collaboration with payers and providers to align payment with real-world performance, thereby mitigating pricing pressure while facilitating access. Fourth, cross-sector collaborations that integrate digital health tools, telemedicine, and remote monitoring can expand reach to underserved populations and support adherence to oral or subcutaneous regimens.

Finally, companies should emphasize transparent engagement with regulators and payers early in development to align on evidentiary requirements and to design pragmatic post-approval evidence-generation plans. By combining operational resilience with clinically focused commercialization strategies, industry leaders can accelerate uptake of innovative therapies while safeguarding long-term sustainability.

Methodological framework combining expert primary research with rigorous secondary synthesis to validate clinical, regulatory, and commercial insights

This research synthesis is grounded in a mixed-methods approach that triangulates primary expert input with comprehensive secondary analysis to provide a robust, defensible perspective on liver cancer therapeutics. Primary research consisted of structured interviews and consultations with clinical thought leaders, oncology pharmacists, payer representatives, and senior commercial executives to capture real-world practice patterns, reimbursement dynamics, and strategic priorities. These expert insights were used to contextualize trends and validate themes emerging from documentary analysis.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map therapeutic advances, trial outcomes, and evidence trajectories. Information from public health agencies and specialty society guidelines was synthesized to understand standard-of-care shifts and diagnostic adoption patterns. Data quality was ensured through cross-referencing of multiple independent sources and iterative validation with subject matter experts.

Limitations of the methodology include the evolving nature of clinical evidence and policy environments, which may change subsequent to the research window. To mitigate this, the approach emphasizes transparent documentation of data provenance and encourages ongoing monitoring of regulatory decisions and major clinical readouts. The methodology balances depth and breadth to support strategic decision-making while acknowledging the need for periodic updates as the field advances.

Final synthesis emphasizing the need to align scientific innovation, operational resilience, and payer-focused evidence to translate therapeutic advances into patient benefit

In conclusion, liver cancer therapeutics are being reshaped by convergent forces: scientific innovation in immuno-oncology and targeted agents, evolving care delivery and administration modalities, and external pressures such as trade policy and regional access disparities. These forces are producing new opportunities for improved patient outcomes while also introducing operational and reimbursement complexities that require coordinated responses from industry, providers, and payers. The net effect is a more dynamic, patient-centric landscape that rewards precision, flexibility, and evidence-driven commercialization.

Moving forward, stakeholders that prioritize diagnostic integration, supply chain resilience, and payer-aligned value demonstration will be better positioned to translate innovation into durable clinical and commercial success. Moreover, adaptive regulatory engagement and strategic partnerships-both clinical and commercial-will remain critical levers for accelerating patient access. Ultimately, the ability to harmonize scientific promise with pragmatic implementation will determine which therapies achieve sustained impact for the diverse populations affected by liver malignancies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of immune checkpoint inhibitor combinations for advanced hepatocellular carcinoma treatment
  • 5.2. Integration of biomarker-driven precision therapies based on genetic profiling in liver cancer management
  • 5.3. Expansion of transarterial radioembolization coupled with systemic therapies in intermediate stage HCC
  • 5.4. Development of next generation CAR T and T cell receptor therapies targeting liver cancer antigens
  • 5.5. Growing emphasis on real-world evidence and digital health monitoring in hepatocellular carcinoma care
  • 5.6. Market access challenges and pricing strategies for novel multi kinase inhibitors in liver cancer therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Cancer Drugs Market, by Therapy Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Radiation Therapy
  • 8.4. Targeted Therapy

9. Liver Cancer Drugs Market, by Cancer Type

  • 9.1. Cholangiocarcinoma
  • 9.2. Hepatoblastoma
  • 9.3. Hepatocellular Carcinoma (HCC)

10. Liver Cancer Drugs Market, by Administration Route

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Liver Cancer Drugs Market, by Drug Class

  • 11.1. Cytotoxic Agents
  • 11.2. Monoclonal Antibodies
  • 11.3. Tyrosine Kinase Inhibitors (TKIs)

12. Liver Cancer Drugs Market, by End User

  • 12.1. Home Care
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Liver Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Liver Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Liver Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Liver Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bayer AG
    • 17.3.2. Eisai Co., Ltd.
    • 17.3.3. Bristol-Myers Squibb Company
    • 17.3.4. Merck & Co., Inc.
    • 17.3.5. F. Hoffmann-La Roche Ltd
    • 17.3.6. Ipsen S.A.
    • 17.3.7. AstraZeneca plc
    • 17.3.8. Exelixis, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 268. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 269. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 310. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 311. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 324. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 325. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 326. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 327. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES LIVER CANCER DRUGS MARKET S